Takaoka, Japan

Masaharu Nakano


Average Co-Inventor Count = 7.2

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 1998-2000

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Masaharu Nakano

Introduction

Masaharu Nakano is a notable inventor based in Takaoka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of peptide derivatives and anticoagulant variants. With a total of three patents to his name, Nakano's work has had a considerable impact on medical science.

Latest Patents

One of Nakano's latest patents involves peptide derivatives that exhibit analgesic activity. These derivatives are represented by a specific formula, where Q can be D-Arg or L-Arg, and X can represent various chemical groups. Typical compounds include H₂NC(NH)-Tyr-D-Arg-Phe-NHCH₂CH₂COOH and H₂NC(NH)-Tyr-D-Arg-Phe-NHCH₂CH₂CONH₂. Another significant patent focuses on anticoagulant hirudin variants and methods for their production. This invention relates to hirudin variants that possess high anti-thrombin and anti-platelet activity, along with methods for producing these variants through sulfation of tyrosine residues.

Career Highlights

Throughout his career, Nakano has worked with prominent companies in the pharmaceutical industry, including Fuji Yakuhin Kogyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to develop innovative solutions that address critical health issues.

Collaborations

Masaharu Nakano has collaborated with several professionals in his field, including Eriko Nukui and Koichi Wada. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Masaharu Nakano's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving medical treatments. His work continues to influence the industry and pave the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…